Medication info

Sitagliptin 25 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletExpired
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablets
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Expired

MFDS item code 202101001 · Approved 2021.02.02

This product's status changed to Expired on 2026.02.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment As dosage adjustment is required based on renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in glycemic control in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. It can be administered as monotherapy, and for patients who have not previously received diabetes pharmacotherapy and find sufficient glycemic control difficult with monotherapy, it is administered in combination with metformin. Additionally, when glycemic control is difficult with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is administered to assist in glycemic management. Even in cases involving multiple medications, adding this medication can be expected to enhance glycemic control effects. This medication is also useful in improving glycemic control in complex treatment scenarios.

Dosage and Administration

Adult dosage

This medication is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment As dosage adjustment is required based on renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Precautions

This medication may cause allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. During the use of this medication, if symptoms of pancreatitis such as abdominal pain, nausea, or vomiting occur, inform medical personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with impaired renal function need dosage adjustments, so regular kidney function tests are required. When taken with other hypoglycemic agents, especially insulin or sulfonylureas, the risk of hypoglycemia may increase, so blood glucose levels should be monitored closely. If severe joint pain or skin blisters appear during treatment with this medication, inform a physician immediately, and discontinue use if necessary. Pregnant or lactating women should not take this medication, and safety in children under 18 has not been established. Elderly patients may have reduced renal function, necessitating dosage adjustments and kidney function testing. In cases of overdose, seek proper treatment at a medical facility immediately, as this medication can be partially removed by hemodialysis. This medication has minimal interactions with other drugs, but it is important to inform medical personnel when taking certain medications.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 33 more
  • nausea
  • peripheral edema
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • elevated low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture infiltration. It should be kept at room temperature between 1 to 30 degrees Celsius, away from extreme heat or cold.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablets

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.